Cue Biopharma (CUE) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 0.2% versus a loss of 68.6%. Over five years, CUE leads with a -94.0% price change compared with -97.9% for NBP. Cue Biopharma is the larger company by market cap ($163.5 million vs $158.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | NBP |
|---|---|---|
| Share price | $22.51 | $1.37 |
| Market cap | $163.52M | $158.92M |
| 1-day change | -2.72% | -2.14% |
| YTD return | +146.01% | -65.58% |
| 1-year return | -0.22% | -68.65% |
| 5-year return | -94.04% | -97.92% |
| EPS (TTM) | $-28.75 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $6.79 |
| 52-week low | $4.98 | $1.31 |
| Distance from 52-week high | -50.53% | -79.82% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +290.94% | +556.93% |
| Average volume | 269.82K | 387.52K |
| Shares outstanding | 7.26M | 116.00M |
| Employees | 29 | 30 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed NBP by 68.4 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Healthcare · Biotechnology · 29 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
CUE vs NBP FAQ
Which is bigger, Cue Biopharma or NovaBridge Biosciences?
Cue Biopharma (CUE) is larger, with a market capitalization of $163.52M compared with $158.92M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, CUE or NBP?
CUE returned -0.22% over the past 12 months, compared with -68.65% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.